Network pharmacology and AI in cancer research uncovering biomarkers and therapeutic targets for RALGDS mutations
Abstract The lack of target therapies is accountable for the higher mortality of various types of cancer. To address this issue, we selected a target mutated Kirsten rat sarcoma virus oncogene homologue, which plays a significant role in various cancers. Our study aims to identify selective biomarke...
Saved in:
| Main Authors: | S. Mohammed Zaidh, Hariharan Thirumalai Vengateswaran, Mohammad Habeeb, Kiran Balasaheb Aher, Girija Balasaheb Bhavar, N. Irfan, K N V Chenchu Lakshmi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-91568-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hepatocellular carcinoma imaging: Exploring traditional techniques and emerging innovations for early intervention
by: Hariharan Thirumalai Vengateswaran, et al.
Published: (2024-12-01) -
The Isoforms of Ral Guanine Nucleotide Dissociation Stimulator (RalGDS) in LLC-PK1 Cells
by: Jingze Song, et al.
Published: (2025-07-01) -
The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis
by: Rui Zhao, et al.
Published: (2024-11-01) -
A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations
by: Jonathan W. Riess, MD, MS, et al.
Published: (2025-06-01) -
KRAS-mutated non-small cell lung cancer: new therapy strategies
by: K. K. Laktionov, et al.
Published: (2024-05-01)